Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28773360 | 0.83 | KMT2A (0.49) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL7134570 | 0.83 | KMT2A (0.52) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL1965001 | 0.83 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL9449395 | 0.81 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL14312060 | 0.81 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL22960720 | 0.80 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL6746183 | 0.79 | KMT2A (0.60) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL22147438 | 0.78 | KMT2A (0.45) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL831613 | 0.77 | KMT2A (0.51) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31756603 | 0.77 | CYP1A2 (0.53) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027227-A1 | NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4674439-A1 | RADIOACTIVE METAL LABELED ANTIBODY, RADIOPHARMACEUTICAL, AND COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250326775-A1 | A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250320310-A1 | A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION | SUZHOU BIOREINNO BIOTECHNOLOGY LTD COMPANY (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4577552-A1 | A NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) | 2025-07-02 | — | — | EP | disclosed |
| EP-4536283-A1 | A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION | SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536670-A1 | A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF | SUZHOU BIOREINNO BIOTECHNOLOGY LIMITED COMPANY (CN) | 2025-04-16 | — | — | EP | disclosed |
| CN-119487044-A | Novel mercaptan reducing agent and preparation method and application thereof | 苏州佰睿壹生物技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119365471-A | Novel thiol reducing agents, methods and uses thereof | 苏州佰睿壹生物技术有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2017-01-12 | — | — | US | disclosed |
| US-9315545-B2 | Hepcidin mimetic peptides and uses thereof | MERGANSER BIOTECH, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | BIOMOLECULAR HOLDINGS LLC | 2016-01-28 | — | — | US | disclosed |
| WO-2015157283-A9 | HEPCIDIN MIMETIC PEPTIDES AND USES THEREOF | MERGANSER BIOTECH LLC (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015157283-A1 | HEPDICIN MIMETIC PEPTIDES AND USES THEREOF | MERGANSER BIOTECH LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150284429-A1 | HEPCIDIN MIMETIC PEPTIDES AND USES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20040086949-A1 | Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof | STATENS SERUM INSTITUT | 2004-05-06 | — | — | US | disclosed |
| EP-1117677-B1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUMINSTITUT (DK) | 2003-11-12 | — | — | EP | disclosed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284429-A1 | HEPCIDIN MIMETIC PEPTIDES AND USES THEREOF | HAMP, FTH1, TFRC | KMT2A 4271/4885FABP5 663/4885FABP7 607/4885 |
| US-20260027227-A1 | NOVEL THIOL REDUCTANT, METHOD AND USE THEREOF | CBR1, SCLY, SSB | KMT2A 4118/4885FABP5 1014/4885FABP7 1948/4885 |
| US-20250326775-A1 | A NOVEL THIOL REDUCTANT, PREPARATION METHOD AND USE THEREOF | TMT1A, TST, PRDX3 | KMT2A 2805/4885FABP5 1564/4885FABP7 1757/4885 |
| US-20250320310-A1 | A METHOD FOR PROGRAMMATICALLY MANAGING ANTIBODY DISULFIDE BONDS SITE-SPECIFIC MODIFICATION | PTMS, PDIA6, SCLY | KMT2A 1122/4885FABP5 1966/4885FABP7 3170/4885 |
| US-20160024226-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, FCGR2A, VSIG8 | KMT2A 2199/4885FABP5 1022/4885FABP7 903/4885 |
| US-20170008950-A1 | HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE | FCGR3B, SCLY, FCGR2A | KMT2A 2998/4885FABP5 148/4885FABP7 314/4885 |
| US-12509502-B2 | Hybrid immunoglobulin containing nonpeptidyl linkage | FCGR2A, FCGR3B, CD74 | KMT2A 3327/4885FABP5 66/4885FABP7 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.